Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Schulman

Showing results (11-20 of 68) with videos related to

Pageof 7
Sort By:
JAMA|June 2, 2021
When Vaccine Apathy, Not Hesitancy, Drives Vaccine DisinterestStacy Wood, Kevin Schulman
Health Services Research|March 2, 2020
The unintended consequences of the 340B safety-net drug discount programSamuel Thomas, Kevin Schulman
Health Services Research|February 15, 2026
Impact of 340B Exposure on Treatment Utilization and Cost for Medicare Patients With CancerDanea M Horn, Kevin Schulman
The New England Journal of Medicine|March 18, 2026
Substandard Generic Drugs - Threats to Patient Safety and National SecurityKevin Schulman, Arthur L Kellermann
American Heart Journal|July 31, 2020
Exploring payments in the US pharmaceutical market from 2011 to 2019: Update on pharmacy benefit manager impactEmery P Weinstein, Kevin Schulman
The American Journal of Medicine|August 27, 2019
Comanagement by Hospitalists: Why It Makes Clinical and Fiscal SenseNidhi Rohatgi, Kevin Schulman, Neera Ahuja
JAMA|January 7, 2022
The Dysfunctional Health Benefits Market and Implications for US Employers and EmployeesDavid Scheinker, Arnold Milstein, Kevin Schulman
The New England Journal of Medicine|April 3, 2020
Covid-19 and Health Care's Digital RevolutionSirina Keesara, Andrea Jonas, Kevin Schulman
NPJ Digital Medicine|October 16, 2024
India's evolving digital health strategyAditya Narayan, Indu Bhushan, Kevin Schulman
JAMA Internal Medicine|January 13, 2021
The COVID-19 Pandemic-An Opportune Time to Update Medical LicensingSamyukta Mullangi, Mohit Agrawal, Kevin Schulman
Pageof 7

Showing results (11-20 of 68) with videos related to

Sort By:
Pageof 7
JAMA|June 2, 2021
When Vaccine Apathy, Not Hesitancy, Drives Vaccine DisinterestStacy Wood, Kevin Schulman
Health Services Research|March 2, 2020
The unintended consequences of the 340B safety-net drug discount programSamuel Thomas, Kevin Schulman
Health Services Research|February 15, 2026
Impact of 340B Exposure on Treatment Utilization and Cost for Medicare Patients With CancerDanea M Horn, Kevin Schulman
The New England Journal of Medicine|March 18, 2026
Substandard Generic Drugs - Threats to Patient Safety and National SecurityKevin Schulman, Arthur L Kellermann
American Heart Journal|July 31, 2020
Exploring payments in the US pharmaceutical market from 2011 to 2019: Update on pharmacy benefit manager impactEmery P Weinstein, Kevin Schulman
The American Journal of Medicine|August 27, 2019
Comanagement by Hospitalists: Why It Makes Clinical and Fiscal SenseNidhi Rohatgi, Kevin Schulman, Neera Ahuja
JAMA|January 7, 2022
The Dysfunctional Health Benefits Market and Implications for US Employers and EmployeesDavid Scheinker, Arnold Milstein, Kevin Schulman
The New England Journal of Medicine|April 3, 2020
Covid-19 and Health Care's Digital RevolutionSirina Keesara, Andrea Jonas, Kevin Schulman
NPJ Digital Medicine|October 16, 2024
India's evolving digital health strategyAditya Narayan, Indu Bhushan, Kevin Schulman
JAMA Internal Medicine|January 13, 2021
The COVID-19 Pandemic-An Opportune Time to Update Medical LicensingSamyukta Mullangi, Mohit Agrawal, Kevin Schulman
Pageof 7